• Explore /
  • Poster
  • / Final analysis: Randomized, blinded, placebo-controlled phase II trial of sorafenib with and without mapatumumab in patients with advanced hepatocellular carcinoma (HCC).

Final analysis: Randomized, blinded, placebo-controlled phase II trial of sorafenib with and without mapatumumab in patients with advanced hepatocellular carcinoma (HCC).

Abstract Poster

Authors

null

Tudor-Eliade Ciuleanu

Prof. Dr. I. Chiricuta Institute of Oncology, Cluj County, Romania

Tudor-Eliade Ciuleanu , Igor Bazin , Dan Lungulescu , Lucian Miron , Igor Bondarenko , Andrzej Deptala , Maribel Rodriguez-Torres , Bruce J. Giantonio , Weijing Sun , Norma Lynn Fox , Gursel Aktan , Paul Stephen Wissel , Jacki Egger , Meichun Ding , Rubana Kalyani , Matthew Joseph Gribbin

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2014 ASCO Annual Meeting

Session Type

Poster Highlights Session

Session Title

Gastrointestinal (Noncolorectal) Cancer

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Other GI Cancer

Clinical Trial Registration Number

NCT01258608

Citation

J Clin Oncol 32:5s, 2014 (suppl; abstr 4029)

DOI

10.1200/jco.2014.32.15_suppl.4029

Abstract #

4029

Poster Bd #

48

Abstract Disclosures

Similar Posters

First Author: Ann-Lii Cheng

First Author: Daniel H. Palmer

First Author: Arndt Vogel

First Author: Richard S. Finn